[Recurrent epistaxis associated with Randu-Osler disease, requiring ligation of the external carotid arteries on both sides].

A rare clinical case of recurrent nosebleeds associated with Randu-Osler disease, in which drug, hemostatic, transfusion therapy and combined nasal tamponade were ineffective, required ligation of the external carotid arteries on both sides, is presented.

[Hemostasis and maintenange of the organism vitamin C].

The analysis of the literature on communication of a hemostasis and vitamin C has allowed to assert, that its deficiency accelerates lipid peroxidation and reduces potential at porpoises, and it conducts to activation platelets, to acceleration of continuous intravascular blood coagulation of and to reduction in tolerance to thrombin. High dozes of vitamin C influences a hemostasis strengthens lipid peroxidation similarly to prooxidizers. Entering high dozes of vitamin C at the statuses menacing weith thromboses, it is desirable to supervise a level of markers of intravascular blood coagulation in plasma.

Effect of inhibitors of arachidonic acid conversion in platelets on thrombin-fibrinogen interaction and thrombin tolerance.

Experiments on 200 rats showed that inhibitors of arachidonic acid conversion capable of reducing coagulation activity of platelets decrease the content of markers for thrombin--fibrinogen interaction in the plasma and, therefore, decelerate intravascular blood coagulation and increase thrombin tolerance.

[Erythrocytes and leucocytes in realization of communication between lipid peroxidation and hemostasis].

Investigation of 213 rats has shown that exposition containing normal plasma of erythrocytes, neutrophils or monocytes (physiological concentration) taken from the rats treated with prooxidant (lead acetate) or antioxidant (selmevite) causes corresponding increase or decrease of: a) both spontaneous aggregation and ATP-induced aggregation of thrombocytes, b) releasing P3 and P4 factors, c) their lipoperoxidation (LPO) intensity. The effect is released by LPO products released by erythrocytes and leucocytes into their environment. The efficacy of antioxidants (vitamins with antioxidant properties in particular) used for correcting hypercoagulative changes in oxidative stress in clinics is supposed to be due to their capacity for limiting lipidoxidation in erythrocytes, leukocytes and thrombocytes.

[The effect of a combined vitamin--antioxidants preparations on hemostasis in rats with experimental hyperperoxidation].

Experiments on a group of 308 rats showed that prooxidant (lead acetate) introduced per os with daily meals decreases the antioxidant potential (increases lipid peroxidation, LPO) and reduces tolerance with respect to thrombin (increases the level of intravascular blood coagulation markers). For the same treatment on the background of a vitamin - antioxidants preparations (complivit or selmevit), the level of changes was significantly decreased and the resistance to thrombin was increased. Selmevit (containing selenium) was more effective.